Rinninella E, Raoul P, Cintoni M, Franceschi F, Miggiano GA, Gasbarrini A, Mele MC. What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases. Microorganisms. 2019;7(1):14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

de Vos WM, Tilg H, Van Hul M, Cani PD. Gut microbiome and health: mechanistic insights. Gut. 2022;71(5):1020–32.

Article  PubMed  Google Scholar 

Khan AA, Sirsat AT, Singh H, Cash P. Microbiota and cancer: current understanding and mechanistic implications. Clin Transl Oncol. 2022;24(2):193–202.

Article  CAS  PubMed  Google Scholar 

Zhang Y, Shen J, Shi X, Du Y, Niu Y, Jin G, Wang Z, Lyu J. Gut microbiome analysis as a predictive marker for the gastric cancer patients. Appl Microbiol Biotechnol. 2021;105:803–14.

Article  CAS  PubMed  Google Scholar 

Zhao Y, Liu Y, Li S, Peng Z, Liu X, Chen J, Zheng X. Role of lung and gut microbiota on lung cancer pathogenesis. J Cancer Res Clin Oncol. 2021;147(8):2177–86.

Article  PubMed  PubMed Central  Google Scholar 

Sánchez-Alcoholado L, Ramos-Molina B, Otero A, Laborda-Illanes A, Ordóñez R, Medina JA, Gómez-Millán J, Queipo-Ortuño MI. The role of the gut microbiome in colorectal cancer development and therapy response. Cancers. 2020;12(6):1406.

Article  PubMed  PubMed Central  Google Scholar 

Sharma J, Huda F, Naithani M, Singh SK, Kumar N, Basu S. Role of gut microbiome and enteric bacteria in gallbladder cancer. In immunology of the GI tract-recent advances 2022. London: IntechOpen; 2022.

Google Scholar 

Park SY, Hwang BO, Lim M, Ok SH, Lee SK, Chun KS, Park KK, Hu Y, Chung WY, Song NY. Oral–gut microbiome axis in gastrointestinal disease and cancer. Cancers. 2021;13(9):2124.

Article  PubMed  PubMed Central  Google Scholar 

Chen YH, Wu WK, Wu MS. Microbiota-associated therapy for non-alcoholic steatohepatitis-induced liver cancer: a review. Int J Mol Sci. 2020;21(17):5999.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang C, Xu J, Xu X, Xu W, Tong B, Wang S, Ji R, Tan Y, Zhu Y. Characteristics of gut microbiota in patients with metabolic associated fatty liver disease. Sci Rep. 2023;13(1):9988.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang F, Lyu B, Xie F, Li F, Xing Y, Han Z, Lai J, Ma J, Zou Y, Zeng H, Xu Z. From gut to liver: unveiling the differences of intestinal microbiota in NAFL and NASH patients. Front Microbiol. 2024;4(15):1366744.

Article  Google Scholar 

Ren Z, Li A, Jiang J, Zhou L, Yu Z, Lu H, Xie H, Chen X, Shao L, Zhang R, Xu S. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut. 2019;68(6):1014–23.

Article  CAS  PubMed  Google Scholar 

Caligiuri A, Gentilini A, Marra F. Molecular pathogenesis of NASH. Int J Mol Sci. 2016;17(9):1575.

Article  PubMed  PubMed Central  Google Scholar 

Thursby E, Juge N. Introduction to the human gut microbiota. Biochem J. 2017;474(11):1823–36.

Article  CAS  PubMed  Google Scholar 

Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, Fernandes GR, Tap J, Bruls T, Batto JM, Bertalan M. Enterotypes of the human gut microbiome. Nature. 2011;473(7346):174–80.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ponziani FR, Nicoletti A, Gasbarrini A, Pompili M. Diagnostic and therapeutic potential of the gut microbiota in patients with early hepatocellular carcinoma. Therapeut Adv Med Oncol. 2019;11:1758835919848184.

CAS  Google Scholar 

Cholankeril G, Patel R, Khurana S, Satapathy SK. Hepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management. World J Hepatol. 2017;9(11):533.

Article  PubMed  PubMed Central  Google Scholar 

Sobhonslidsuk A, Chanprasertyothin S, Pongrujikorn T, Kaewduang P, Promson K, Petraksa S, Ongphiphadhanakul B. The association of gut microbiota with nonalcoholic steatohepatitis in Thais. Biomed Res Int. 2018;16:2018.

Google Scholar 

Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–57.

Article  PubMed  Google Scholar 

Nair B, Kamath AJ, Tergaonkar V, Sethi G, Nath LR. Mast cells and the gut-liver Axis: implications for liver disease progression and therapy. Life Sci. 2024;10: 122818.

Article  Google Scholar 

Yu J, Marsh S, Hu J, Feng W, Wu C. The pathogenesis of nonalcoholic fatty liver disease: interplay between diet, gut microbiota, and genetic background. Gastroenterol Res Pract. 2016;2016(1):2862173.

PubMed  PubMed Central  Google Scholar 

Albillos A, De Gottardi A, Rescigno M. The gut-liver axis in liver disease: pathophysiological basis for therapy. J Hepatol. 2020;72(3):558–77.

Article  CAS  PubMed  Google Scholar 

Gupta H, Youn GS, Shin MJ, Suk KT. Role of gut microbiota in hepatocarcinogenesis. Microorganisms. 2019;7(5):121.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang C, Yang M, Ericsson AC. The potential gut microbiota-mediated treatment options for liver cancer. Front Oncol. 2020;14(10): 524205.

Article  Google Scholar 

Ohtani N, Hara E. Gut-liver axis-mediated mechanism of liver cancer: a special focus on the role of gut microbiota. Cancer Sci. 2021;112(11):4433–43.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chu H, Williams B, Schnabl B. Gut microbiota, fatty liver disease, and hepatocellular carcinoma. Liver Res. 2018;2(1):43–51.

Article  PubMed  PubMed Central  Google Scholar 

Young VB. The role of the microbiome in human health and disease: an introduction for clinicians. BMJ. 2017;15:356.

Google Scholar 

Olszak T, An D, Zeissig S, Vera MP, Richter J, Franke A, Glickman JN, Siebert R, Baron RM, Kasper DL, Blumberg RS. Microbial exposure during early life has persistent effects on natural killer T cell function. Science. 2012;336(6080):489–93.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Loo TM, Kamachi F, Watanabe Y, Yoshimoto S, Kanda H, Arai Y, Nakajima-Takagi Y, Iwama A, Koga T, Sugimoto Y, Ozawa T. Gut microbiota promotes obesity-associated liver cancer through PGE2-mediated suppression of antitumor immunitygut microbiota promotes obesity-linked HCC via immune escape. Cancer Discov. 2017;7(5):522–38.

Article  CAS  PubMed  Google Scholar 

Kang Y, Cai Y, Yang Y. The gut microbiome and hepatocellular carcinoma: Implications for early diagnostic biomarkers and novel therapies. Liver Cancer. 2021;11:113.

Article  PubMed  PubMed Central  Google Scholar 

Le Roy T, Llopis M, Lepage P, Bruneau A, Rabot S, Bevilacqua C, Martin P, Philippe C, Walker F, Bado A, Perlemuter G. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut. 2013;62(12):1787–94.

Article  PubMed  Google Scholar 

Wang X, Zhang L, Dong B. Molecular mechanisms in MASLD/MASH related HCC. Hepatology. 2024;13:10–97.

CAS  Google Scholar 

Kolodziejczyk AA, Zheng D, Shibolet O, Elinav E. The role of the microbiome in NAFLD and NASH. EMBO Mol Med. 2019;11(2): e9302.

Article  PubMed  Google Scholar 

Abdul-Hai A, Abdallah A, Malnick SD. Influence of gut bacteria on development and progression of non-alcoholic fatty liver disease. World J Hepatol. 2015;7(12):1679.